BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Amarin, Secura Bio Face Disappointing Data, FDA Warning

  Amarin released disappointing post hoc data from a sub-study of the REDUCE-IT trial, showing that its fish oil-derived Vascepa had little impact on serum biomarkers.

  July 1, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Clinical Catch-Up: Alzheimer’s, MS and Cancer Headline Trial News

  Otsuka and Lunbeck report positive Phase III results in agitation in Alzheimer’s, Acer’s vEDS program hits Phase III and BridgeBio’s primary hyperoxaluria type 1 program progresses.

  July 1, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  NYU Researchers Create Synthetic Versions of Hox Genes

  A team of researchers at New York University has successfully created synthetic versions of the Hox genes that control biological development in humans.

  July 1, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Business

  Novartis May Turn Sandoz into Separate Entity Amidst Restructuring

  Rather than selling, Novartis could spin Sandoz off into its own separate entity with its own listing on a stock exchange.

  July 1, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  FDA Reportedly OK’s Future Trial For Pig-to-Human Organ Transplantation

  Citing an unnamed FDA insider, the regulator is in the process of devising a plan to enable clinical testing on a larger scale.

  July 1, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Heron, Avadel Slash Headcount, Brace for Economic Downturn

  Heron Therapeutics and Avadel Pharmaceuticals have now joined the ranks of life sciences companies cutting costs including laying off a significant number of employees.

  July 1, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Hyloris’ Post-Op Pain Treatment Maxigesic IV Stalled by CRL from FDA

  Hyloris did not provide details on the FDA’s concern regarding Maxigesic IV but said it will fully comply with whatever is necessary to move the product forward.

  July 1, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Job Trends

  Continuing Transformation, Bayer Opens Genetown Research and Innovation Center

  Cambridge, Massachusetts’ Kendall Square just got a little more crowded following the announcement that life sciences giant Bayer opened its new Research and Innovation Center.

  July 1, 2022

   · 

  5 min read

   · 

  Alex Keown
• 

  Business

  FDA Declines EAU, SCOTUS’ Thomas Weighs in on Vaccine & More COVID-19 News

  Companies are still developing and refining treatments and preventions for COVID-19, but not all of them are approved or authorized. Here’s a look at the latest COVID-19 news.

  July 1, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Provention Bio Announces FDA Extension of Diabetes Drug Review

  Provention Bio announced the FDA extended its review period by three months for the Biologics License Application (BLA) of its diabetes prevention drug, teplizumab to Nov. 17.

  July 1, 2022

   · 

  2 min read

   · 

  Alex Keown